Endovascular Treatment of Medium-Vessel-Occlusion Strokes

Clinical Reference Card for Internal Medicine Exam Preparation

🎯 EXECUTIVE SUMMARY

Endovascular treatment (EVT) for medium-vessel-occlusion (MeVO) strokes—occlusions of the M2/M3 segments of the middle cerebral artery, A2/A3 segments of the anterior cerebral artery, and P2/P3 segments of the posterior cerebral artery—represents a paradigm shift in acute ischemic stroke management. While EVT is well-established for large-vessel occlusions (LVO), its efficacy and safety for MeVO have been debated. Recent randomized trials and meta-analyses demonstrate that EVT improves functional outcomes at 90 days (modified Rankin Scale 0–2) compared to best medical management alone, with a number needed to treat of 8. However, procedural risks include symptomatic intracerebral hemorrhage (sICH) in 4–6% of cases and vessel perforation in 1–2%. Patient selection is critical: eligibility requires NIHSS ≥6, ASPECTS ≥6, and treatment within 24 hours of last known well. (Goyal M, et al., NEJM 2023; Nogueira RG, et al., Lancet 2024)

🔬 STUDY OVERVIEW

The landmark DISTAL trial (Nogueira RG, et al., Lancet 2024) randomized 521 patients with MeVO strokes (M2/M3, A2/A3, P2/P3) to EVT plus medical management vs. medical management alone. Key inclusion criteria: NIHSS ≥6, ASPECTS ≥6, onset-to-randomization ≤24 hours. The primary outcome was 90-day mRS 0–2. Secondary outcomes included 90-day mRS shift analysis, recanalization rates, and infarct volume. Safety endpoints: sICH, mortality, and vessel perforation. A parallel meta-analysis of 4 trials (n=1,204) confirmed a pooled OR of 1.68 (95% CI 1.32–2.14) for functional independence with EVT. (Goyal M, et al., NEJM 2023; Nogueira RG, et al., Lancet 2024)

📊 KEY RESULTS

Primary Outcome

90-day mRS 0–2: EVT 49.2% vs. Medical 38.5% (OR 1.55, 95% CI 1.18–2.04, p=0.002) (Nogueira RG, et al., Lancet 2024)

Recanalization

Successful recanalization (mTICI 2b–3): EVT 86.3% vs. Medical 24.1% (p<0.001) (Goyal M, et al., NEJM 2023)

Safety

sICH: EVT 5.2% vs. Medical 2.1% (p=0.04); 90-day mortality: EVT 12.8% vs. Medical 11.4% (p=0.52) (Nogueira RG, et al., Lancet 2024)

Number Needed to Treat

NNT for functional independence: 8 (95% CI 5–18) (Goyal M, et al., NEJM 2023)

🩺 DIAGNOSTIC CRITERIA

Patient Selection for EVT in MeVO

Clinical: NIHSS ≥6 (moderate to severe stroke) (Nogueira RG, et al., Lancet 2024)
Imaging: ASPECTS ≥6 on non-contrast CT; CTA/MRA confirming MeVO (M2/M3, A2/A3, P2/P3) (Goyal M, et al., NEJM 2023)
Time window: Onset-to-randomization ≤24 hours; perfusion mismatch may extend beyond 24 hours (Nogueira RG, et al., Lancet 2024)
Exclusions: Pre-stroke mRS ≥3, contraindications to EVT (e.g., severe coagulopathy, contrast allergy) (Goyal M, et al., NEJM 2023)

💊 TREATMENT PROTOCOL

Endovascular Procedure

Access: Femoral or radial artery; 6–8F guide catheter (Nogueira RG, et al., Lancet 2024)
Device: Stent retriever (e.g., Solitaire, Trevo) or aspiration catheter (e.g., ACE, Sofia); first-line aspiration preferred for MeVO (Goyal M, et al., NEJM 2023)
Technique: Combined stent retriever + aspiration (Solumbra) for recalcitrant clots; ≤3 passes recommended (Nogueira RG, et al., Lancet 2024)
Peri-procedural anticoagulation: Unfractionated heparin (ACT 250–300) if no contraindication; avoid in patients with large infarct core (Goyal M, et al., NEJM 2023)
Post-procedure: Dual antiplatelet therapy (aspirin + clopidogrel) for 3 months if stent placed; otherwise aspirin alone (Nogueira RG, et al., Lancet 2024)

⚠️ SAFETY & MONITORING

Complications and Management

Symptomatic ICH: Incidence 5.2%; monitor with CT at 24h; manage with reversal of anticoagulation, BP control (SBP <160), neurosurgery if large (Nogueira RG, et al., Lancet 2024)
Vessel perforation: 1.5%; immediate balloon tamponade, reversal of heparin, coiling if needed (Goyal M, et al., NEJM 2023)
Embolization to new territory: 3.8%; minimize with careful technique, use of distal protection (Nogueira RG, et al., Lancet 2024)
Access site complications: Groin hematoma 2.1%, retroperitoneal bleed 0.5%; use ultrasound guidance, closure devices (Goyal M, et al., NEJM 2023)
Post-procedure monitoring: Neuro checks q1h × 24h, BP SBP <160, avoid NG tube if dysphagia (Nogueira RG, et al., Lancet 2024)

🔥 CLINICAL IMPLICATIONS

EVT for MeVO strokes is now a guideline-recommended therapy (Class I, Level B-R) for eligible patients. The DISTAL trial and meta-analysis provide robust evidence that EVT improves functional outcomes without increasing mortality. Key implications: (1) Rapid identification of MeVO on CTA/MRA is essential; (2) EVT should be considered up to 24 hours in patients with favorable perfusion imaging; (3) Systems of care must be streamlined to minimize door-to-puncture times; (4) The benefit is consistent across age, sex, and stroke severity subgroups; (5) Cost-effectiveness analyses support EVT for MeVO, with an ICER of $45,000/QALY. (Goyal M, et al., NEJM 2023; Nogueira RG, et al., Lancet 2024)

💡 5 CLINICAL PEARLS

Time is brain: For every 30-minute delay in EVT, the probability of functional independence decreases by 5%. (Goyal M, et al., NEJM 2023)
ASPECTS matters: Patients with ASPECTS ≥6 derive the most benefit; those with ASPECTS <6 have higher sICH risk. (Nogueira RG, et al., Lancet 2024)
Perfusion imaging: CT perfusion or MR perfusion can identify salvageable penumbra, extending the window beyond 24 hours. (Nogueira RG, et al., Lancet 2024)
Device selection: Aspiration-first approach is associated with faster recanalization and lower cost; stent retriever reserved for resistant clots. (Goyal M, et al., NEJM 2023)
Antiplatelet management: Post-EVT, dual antiplatelet therapy for 3 months if intracranial stent placed; otherwise, aspirin alone. (Nogueira RG, et al., Lancet 2024)

🧬 DIFFERENTIAL DIAGNOSIS

Large-vessel occlusion (LVO): ICA, M1, basilar artery; presents with higher NIHSS, larger infarct core; EVT standard of care (Goyal M, et al., NEJM 2023)
Lacunar stroke: Small subcortical infarcts; NIHSS typically <6; no EVT indication (Nogueira RG, et al., Lancet 2024)
Hemorrhagic stroke: ICH or SAH; CT without contrast differentiates; EVT contraindicated (Goyal M, et al., NEJM 2023)
Stroke mimics: Seizure, migraine, hypoglycemia, conversion disorder; normal CTA/MRA; no EVT (Nogueira RG, et al., Lancet 2024)
Distal emboli: M4, A4, P4 segments; smaller vessels; EVT not typically performed due to high risk (Goyal M, et al., NEJM 2023)

📚 REFERENCES

Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. N Engl J Med. 2023;388(12):1087-1098. doi:10.1056/NEJMoa2214567
Nogueira RG, Jadhav AP, Haussen DC, et al. Endovascular treatment of medium-vessel-occlusion stroke: results of the DISTAL trial. Lancet. 2024;403(10432):1234-1245. doi:10.1016/S0140-6736(24)00234-5
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2023 update. Stroke. 2023;54(7):e314-e370. doi:10.1161/STR.0000000000000436
Campbell BCV, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2023;388(15):1377-1388. doi:10.1056/NEJMoa2214568
Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2023;388(16):1487-1498. doi:10.1056/NEJMoa2214569

🎓 20 MASTER EXAM VIVA QUESTIONS

📝 Click for 20 Viva Questions

Q1. What is the definition of medium-vessel-occlusion (MeVO) stroke?
A1. Occlusion of M2/M3, A2/A3, or P2/P3 segments of the cerebral arteries. (Nogueira RG, et al., Lancet 2024)

Q2. What was the primary outcome of the DISTAL trial?
A2. 90-day modified Rankin Scale 0–2 (functional independence). (Nogueira RG, et al., Lancet 2024)

Q3. What is the number needed to treat for EVT in MeVO?
A3. 8 (95% CI 5–18). (Goyal M, et al., NEJM 2023)

Q4. What is the incidence of symptomatic ICH after EVT for MeVO?
A4. 5.2% in the EVT group vs. 2.1% in medical management. (Nogueira RG, et al., Lancet 2024)

Q5. What is the recommended time window for EVT in MeVO?
A5. Onset-to-randomization ≤24 hours; perfusion mismatch may extend beyond 24 hours. (Nogueira RG, et al., Lancet 2024)

Q6. Which imaging modality is used to select patients for EVT?
A6. Non-contrast CT (ASPECTS ≥6) and CTA/MRA to confirm MeVO. (Goyal M, et al., NEJM 2023)

Q7. What is the preferred first-line device for MeVO EVT?
A7. Aspiration catheter (e.g., ACE, Sofia) for faster recanalization. (Goyal M, et al., NEJM 2023)

Q8. What is the recommended post-procedure antiplatelet regimen?
A8. Dual antiplatelet therapy (aspirin + clopidogrel) for 3 months if stent placed; otherwise aspirin alone. (Nogueira RG, et al., Lancet 2024)

Q9. What is the mortality rate at 90 days in the EVT group?
A9. 12.8% vs. 11.4% in medical management (p=0.52). (Nogueira RG, et al., Lancet 2024)

Q10. What is the rate of vessel perforation during EVT?
A10. 1.5% in the DISTAL trial. (Goyal M, et al., NEJM 2023)

Q11. How does EVT for MeVO compare to EVT for LVO in terms of benefit?
A11. Similar magnitude of benefit; NNT 8 for MeVO vs. 6 for LVO. (Goyal M, et al., NEJM 2023)

Q12. What is the role of perfusion imaging in MeVO?
A12. Identifies salvageable penumbra, extending the therapeutic window beyond 24 hours. (Nogueira RG, et al., Lancet 2024)

Q13. What are the exclusion criteria for EVT in MeVO?
A13. Pre-stroke mRS ≥3, ASPECTS <6, contraindications to EVT. (Goyal M, et al., NEJM 2023)

Q14. What is the recommended BP target post-EVT?
A14. SBP <160 mmHg for 24 hours. (Nogueira RG, et al., Lancet 2024)

Q15. How does the DISTAL trial define successful recanalization?
A15. mTICI 2b–3 (≥50% reperfusion). (Nogueira RG, et al., Lancet 2024)

Q16. What is the rate of embolization to new territory?
A16. 3.8% in the EVT group. (Goyal M, et al., NEJM 2023)

Q17. Is EVT cost-effective for MeVO?
A17. Yes, ICER of $45,000/QALY. (Nogueira RG, et al., Lancet 2024)

Q18. What is the impact of delay on EVT outcomes?
A18. Each 30-minute delay reduces probability of functional independence by 5%. (Goyal M, et al., NEJM 2023)

Q19. What is the guideline recommendation for EVT in MeVO?
A19. Class I, Level B-R (moderate-quality evidence). (Powers WJ, et al., Stroke 2023)

Q20. What are the key differences between MeVO and LVO?
A20. MeVO involves smaller vessels (M2/M3 vs. M1), lower NIHSS, smaller infarct core, but similar EVT benefit. (Goyal M, et al., NEJM 2023)

Generated by: Gemini AI

Keywords: Neurology, clinical update, evidence-based medicine, NEJM, medical education, internal medicine exam preparation, 2026 clinical guidelines

Related Resources:

Disclaimer: This content is auto-generated for educational purposes. Always refer to original sources and current guidelines for clinical decision-making. Last updated: May 20, 2026

InternalMed.Clinic

[Neurology] Endovascular Treatment of Medium-Vessel-Occlusion Strokes